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Background. Self-reported sleep quality is poor in persons with human immunodeficiency virus (PWH), but prior studies com-
monly used nonspecific questionnaires, investigated only single sleep disorders, or lacked human immunodeficiency virus (HIV)-
negative controls. We addressed these limitations in the Pharmacokinetics and Clinical Observations in People Over Fifty (POPPY) 
Sleep Substudy by assessing PWH and HIV-negative controls for insomnia, restless legs syndrome (RLS), and sleep apnea (SA).
Methods. Previously enrolled POPPY participants coenrolled in this substudy without regard to sleep symptoms. Participants com-
pleted validated sleep assessments including the Insomnia Severity Index questionnaire, International Restless Legs Syndrome Study 
Group questionnaire, and in-home, wrist-worn overnight oximetry. They also completed health-related quality of life questionnaires in-
cluding 36-item Short Form (SF-36) and Patient-Reported Outcomes Measurement Information System (PROMIS) sleep questionnaires.
Results. We enrolled 357 PWH (246 >50 years of age; 111 between 18 and 50 years) and 126 HIV-negative controls >50 years 
of age. Among PWH, criteria were met by 21% for insomnia, 13% for RLS, and 6% for SA. Compared with HIV-negative controls, 
PWH had a higher risk of insomnia (adjusted odds ratio, 5.3; 95% confidence interval, 2.2–12.9) but not RLS or SA. Compared with 
PWH without insomnia, those with insomnia reported significantly worse scores on all SF-36 and PROMIS components; fewer than 
30% reported previous diagnosis or treatment for insomnia.
Conclusions. Insomnia was more common in PWH, associated with worse health-related quality of life, and frequently undi-
agnosed. Further research should focus on the pathogenesis of insomnia in PWH and the development of effective screening and 
intervention strategies for this unique population.
Keywords.  HIV; insomnia; patient reported outcomes measures; restless legs syndrome; sleep apnea syndromes.
Sleep disorders such as sleep apnea (SA), insomnia, and restless 
legs syndrome (RLS) are increasingly common as people age [1–3], 
and these sleep disorders can have substantial impact on quality of 
life (QoL). Studies also suggest that the presence of sleep disorders 
increases the risk for long-term adverse health consequences such 
as cardiovascular disease and cognitive decline [4, 5].
Persons with human immunodeficiency virus (PWH) are 
now increasingly older [6], and many studies have reported 
poor sleep quality in PWH [7–11]. However, sleep quality in 
PWH has most commonly been measured using nonspecific 
questionnaires such as the Pittsburgh Sleep Quality Index 
(PSQI), which do not identify specific sleep disorders a person 
might have.
Several studies have assessed populations of PWH for spe-
cific sleep disorders such as SA [12, 13] or insomnia [14–16]], 
but most were single-center studies, relatively small, focused 
on single sleep disorders, and often lacked human immunode-
ficiency virus (HIV)-negative controls. We simultaneously as-
sessed for common sleep disorders (SA, insomnia, and RLS) 
in an established cohort of PWH and lifestyle-matched HIV-
negative controls to estimate the prevalence of these sleep dis-
orders, determine whether prevalence differs by HIV status, and 
test associations between sleep disorders and health-related QoL.
METHODS
Study Design and Participants
The Pharmacokinetics and Clinical Observations in People 
Over Fifty (POPPY) study is an observational cohort study 
that enrolled adult participants from 7 sites in England and 






/ofid/article/8/1/ofaa561/5989004 by guest on 05 January 2021
2 • ofid • Kunisaki et al
1 in Ireland [17]. Enrollment was specifically targeted to 
include PWH >50  years of age (“Older PWH”), along with 
demographically similar PWH 18–50 years of age (“Younger 
PWH”) and HIV-seronegative controls >50 years of age re-
cruited from sexual health clinics and healthcare settings 
affiliated with the POPPY HIV sites (“Older HIV-Negative 
Controls”) such that the controls were considered “at risk” 
for HIV, but seronegative. For this POPPY-Sleep substudy, 
inclusion criteria required that participants were previously 
enrolled in the main POPPY study and be able to wear a 
fingertip oximetry device and wrist actigraph. The only ex-
clusion criterion was an investigator’s judgment that the par-
ticipant was unlikely to adhere to study procedures. Potential 
participants were identified without regard to sleep symp-
toms or previous sleep diagnoses.
Patient Consent Statement
All participants provided written informed consent. The pro-
tocol was approved by the UK National Health Service Health 
Research Authority and appropriate local ethics committees 
and institutional review boards.
Procedures
Participants completed a study visit to undergo consent and 
questionnaires, followed by a single night of in-home overnight 
pulse oximetry using a battery-powered, wrist-worn overnight 
fingertip pulse oximetry device (WristOx 3150; Nonin Medical, 
Plymouth, MN) with high-resolution sampling (1 sample per 
second) throughout a single night. Raw oximetry data were 
downloaded at the study site and electronically transferred to the 
Sleep Reading Center (Brigham and Women’s Hospital, Boston, 
MA) for central quality control review and retesting requests 
when <3 hours of artifact-free data were found. Recordings 
were annotated to identify periods of likely “lights off,” “lights 
on”, and artifact. After annotations, records were processed to 
generate various oxygen saturation metrics. This analysis fo-
cused on 4% oxygen desaturation index (ODI), scored as the 
number of times per hour that the oxygen saturation decreased 
by 4% or greater from a local baseline. We categorized partici-
pants with ODI ≥5/hour as having SA, because multiple studies 
have shown high predictive ability of overnight oximetry to dis-
criminate the presence or absence of SA (C-statistics between 
0.86 to 0.96) [18–20]. Sleep apnea can be caused by both airway 
obstruction events (ie, obstructive SA) and by central respira-
tory drive events (ie, central SA), but overnight oximetry does 
not distinguish between obstructive and central events, hence 
our use of the generic term “sleep apnea.”
Participants also completed questionnaires. The Insomnia 
Severity Index (ISI) is a validated, 7-item, self-reported ques-
tionnaire designed to detect insomnia [21]. A  Likert scale of 
0 to 4 points is used for each of the 7 items, for a total score 
range of 0–28. The ISI questions are directed to symptoms over 
the previous 2 weeks, and scores are interpreted as no insomnia 
(0–7), subthreshold insomnia (8–14), moderate insomnia (15–
21), and severe insomnia (22–28). In this analysis, we classified 
those reporting scores of 15 or higher as having insomnia.
The 2003 International Restless Legs Syndrome Study Group 
(IRLSSG) questionnaire for RLS assessment in epidemiologic 
studies is a 4-item questionnaire, with 3 dichotomous yes/
no questions targeted at key RLS symptoms, and 1 question 
to assess the frequency of such symptoms [22]. Participants 
who responded yes to all 3 key symptoms were classified as 
RLS-positive.
Participants completed sleep-related QoL assessments using 
the Patient-Reported Outcomes Measurement Information 
System (PROMIS) questionnaires for sleep disturbance and 
sleep-related impairment 8-item short forms [23]. They also 
self-reported whether they had been previously diagnosed or 
treated for SA, insomnia, and RLS; formal review of medical 
records was not performed. Medical Outcomes Study, 36-item 
Short Form (SF-36) surveys were also used to calculate Physical 
Component Summary (PCS) and Mental Component Summary 
(MCS) scores [24, 25].
Statistical Analysis
We used Wilcoxon rank-sum, χ 2, or Fisher’s exact tests, as ap-
propriate, to compare the 3 enrollment groups (older PWH, 
younger PWH, older HIV-negative controls) for clinical and 
demographic characteristics, as well as the presence of SA 
(ODI ≥5/hour), insomnia (ISI ≥15), and RLS (3 of 3 positive 
key RLS symptoms), the number of these conditions, self-
reported diagnoses of these conditions, and self-reported pre-
vious or current treatment of these conditions.
In further analyses, we pooled the older and younger PWH 
together and compared the PWH participants to the older 
HIV-negative group. In these analyses, the association of HIV 
with each sleep disorder (SA, insomnia, and RLS) and having 
2 or more sleep disorders were tested using logistic regression 
models, adjusting for age, sex, and ethnicity. We also tested the 
association between the presence and the number of these sleep 
disorders and scores from PROMIS and SF-36 questionnaires, 
using median regression, adjusted for age, sex, and ethnicity, 
stratified by HIV status. We also tested for an HIV interaction 
on these associations.
RESULTS
Between March 13, 2017 and July 31, 2018, we enrolled 483 par-
ticipants with characteristics shown in Table 1. Median (inter-
quartile range [IQR]) time from the main POPPY visit to the 
POPPY-Sleep substudy visit was 9.0 (IQR, 2.3–17.7) months. 
The older and younger PWH groups were generally similar, al-
though the older group had larger median waist circumference 
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Table 1. Demographic and Clinical Characteristics of Study Participants
Median (IQR) or n (%) Older PWH (n = 246) Younger PWH (n = 111) Older HIV, Controls (n = 126) Pa “Aging” Pb ”HIV” Pc
Gender    .18 <.001 .02
 Male 213 (86.6%) 90 (81.1%) 85 (67.5%)    
 Female 33 (13.4%) 21 (18.9%) 41 (32.5%)    
Age [years] 60 (56–65) 46 (40–50) 61 (57–66) <.001 .05 <.001
Ethnicity    .01 .96 .04
 Back African 25 (10.2%) 22 (20.0%) 13 (10.3%)    
 White 221 (89.8%) 89 (80.2%) 113 (89.7%)    
Sexuality    .05 <.001 .002
 MSM/homosexual 198 (80.5%) 79 (71.2%) 65 (51.6%)    
 Heterosexual 48 (19.5%) 32 (28.8%) 61 (48.4%)    
Educational attainmentd,e    .35 .48 .81
 Higher attainment 179 (72.8%) 86 (77.5%) 96 (76.2%)    
 Lower attainment 67 (27.2%) 25 (22.5%) 30 (23.8%)    
Years of educationd 15 (12–18) 17 (13–19) 16 (13–18) .03 .24 .29
Marital Statusd    .04 .003 <.001
 Single 115 (46.7%) 60 (54.1%) 36 (28.6%)    
 Married/in a relationship 107 (43.5%) 48 (43.2%) 75 (59.5%)    
 Divorced/widowed 24 (9.8%) 3 (2.7%) 15 (11.9%)    
Alcohol Consumptiond    .12 .004 .21
 Never consumed 15 (6.1%) 9 (8.1%) 5 (4.0%)    
 Previous consumption 39 (15.9%) 9 (8.1%) 6 (4.7%)    
 Current consumption 192 (78.0%) 93 (83.8%) 115 (91.3%)    
Smoking Statusd    .07 .03 .02
 Never smoked 91 (37.1%) 52 (46.9%) 61 (48.4%)    
 Exsmoker 92 (37.6%) 28 (25.2%) 47 (37.3%)    
 Current smoker 62 (25.3%) 31 (27.9%) 18 (14.3%)    
Ever injected drugsd 23 (9.4%) 10 (9.2%) 2 (1.6%) .96 .005 .008
Recent use of recreational drugsd 61 (24.8%) 33 (29.7%) 18 (14.3%) .33 .02 .004
Height [cm] 174 (169–179) 176 (169–181) 172 (166–179) .08 .17 .02
Weight [kg] 77.4 (69.6–88.0) 79.0 (72.4–85.1) 77.9 (69.9–90.0) .37 .62 .68
BMI [kg/m2] 25.6 (23.5–28.8) 25.2 (23.5–28.1) 26.0 (23.8–29.7) .77 .17 .15
Waist circumference [cm] 95.0 (89.0–102.0) 91.5 (85.0–99.0) 96.0 (88.5–103.0) .007 .89 .02
Neck circumference [cm] 39.5 (37.5–42.0) 39.0 (36.7–41.0) 38.5 (36.0–41.3) .09 .02 .61
Current CD4+ countd [cells/µL] 597 (470–780) 610 (470–779) n/a .76 n/a n/a
Nadir CD4+ count [cells/µL] 179 (80–270) 270 (131–413) n/a <.001 n/a n/a
HIV RNA <40 copies/mLd 224 (91.8%) 99 (90.0%) n/a .58 n/a n/a
On antiretroviral treatment 227 (92.2%) 100 (90.1%)  .49   
Antiretroviral Regimen       
 NNRTI 102 (44.9%) 47 (47.0%) n/a .73   
  Efavirenz 35 (15.4%) 18 (18.0%) n/a .56   
  Nonefavirenz NNRTI 67 (29.5%) 29 (29.0%) n/a .92   
 INSTI 53 (23.4%) 21 (21.0%) n/a .64   
  Dolutegravir 23 (10.1%) 7 (7.0%) n/a .37   
  Raltegravir 23 (10.1%) 7 (7.0%) n/a .37   
  Elvitegravir 7 (3.1%) 7 (7.0%) n/a .11   
 PI 79 (34.8%) 31 (31.0%) n/a .50   
 NRTI 193 (85.0%) 90 (90.0%) n/a .22   
Other medicationsf       
 Sleep aids 26 (10.6%) 8 (7.2%) 3 (2.4%) .32 .004 .12
 Metal health medications 33 (13.4%) 19 (17.1%) 7 (5.6%) .36 .02 .005
 Analgesics 43 (17.5%) 22 (19.8%) 12 (9.5%) .60 .04 .02
Abbreviations: BMI, body mass index; HIV, human immunodeficiency virus; INSTI, integrase strand transfer inhibitor; iqr, interquartile range; NNRTI, nonnucleoside reverse-transcriptase 
inhibitor; PI, protease inhibitor; PWH, persons with HIV; MSM, men whom have sex with men; n/a, not applicable; NRTI, nucleoside reverse-transcriptase inhibitor; RNA, ribonucleic acid.
aTest between older PWH and younger PWH.
bTest between older PWH and older HIV-negatives.
cTest between younger PWH and older HIV-negatives.
dAssessed at POPPY baseline study visit.
eHigher educational attainment defined as A-level, University, or Professional certification; lower as all others.
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cells/mm3 lower; P < .001). Comparing the older PWH and 
older HIV-negative controls, the older PWH included more 
men (87% vs 68%; P < .001), more men who have sex with men/
homosexual persons (81% vs 52%; P < .001), fewer persons 
married or in a relationship (44% vs 60%; P = .003), less alcohol 
(78% vs 91%; P = .004), but more smoking (25% vs 14% cur-
rent smokers; P = .03) and drug use (9% vs 2% injection drug 
use history; P = .005; 25% vs 14% recent recreational drug use; 
P = .02).
Among the 3 sleep disorders for which we assessed, study 
participants most commonly met validated criteria for in-
somnia, followed by RLS, then SA (Table  2). Criteria for at 
least 1 sleep disorder were met by 36% of PWH and 23% of 
the HIV-negative controls; few reported previous diagnosis or 
treatment. Less than 30% of those meeting ISI criteria for in-
somnia reported a prior diagnosis or treatment, whereas pre-
vious diagnosis or treatment for RLS and SA was rare (0% to 
12%). All further references to insomnia, RLS, and SA will refer 
to these disorders per study protocol criteria as described in the 
methods, rather than self-reported diagnosis.
Persons with HIV had significantly higher odds of meeting 
criteria for insomnia (adjusted odds ratio [aOR], 5.26; 95% con-
fidence interval [CI], 2.15–12.85), but not RLS or SA (Figure 1). 
Insomnia was associated with worse physical, mental, sleep dis-
turbance, and sleep-related impairment scores in PWH, and 
with worse sleep disturbance and sleep-related impairment 
scores in HIV-negative controls (Table  3). Restless legs syn-
drome was not associated with any of these outcomes in either 
PWH or HIV-negative controls (Table 4). Sleep apnea was as-
sociated with worse mental health in PWH, but no other out-
comes in PWH or HIV-negative controls (Table 5).
The number of participants meeting criteria for multiple sleep 
disorders was small (n = 17 PWH and n = 5 HIV-negative con-
trols; Supplemental Figure), but among PWH, as the number 
of sleep disorders increased, physical, mental, and sleep-related 
QoL scores were all worse (Supplemental Table). Among HIV-
negative controls, as the number of sleep disorders increased, 
sleep disturbance scores worsened, as well as sleep-related im-
pairment and mental scores, although these last 2 were not sta-
tistically significant in this analysis with limited power.
DISCUSSION
We find that PWH most commonly meet validated question-
naire criteria for insomnia, followed by validated questionnaire 
criteria for RLS, then SA by objectively assessed overnight ox-
imetry criteria. More importantly, when we compare the prev-
alence of these conditions to that in HIV-negative controls, we 
find that PWH are at substantially increased risk for insomnia 
(aOR, 5.26; 95% CI, 2.15–12.85), but not RLS or SA. Moreover, 
despite the high prevalence of insomnia in our PWH study par-
ticipants (21% met criteria for insomnia), less than one third 
of these participants reported ever being diagnosed or treated 
for insomnia. These findings have several important clinical 
implications.
The finding that PWH are at higher risk for insomnia than 
HIV-negative controls has previously been suggested by other 
studies, although a 2014 systematic review was unable to assess 
insomnia prevalence in PWH, because none of the 19 publi-
cations that met their search criteria used validated insomnia 
instruments like the ISI [26]. A  more recent single-center 
study administered the ISI questionnaire to 254 PWH, without 
HIV-negative controls, and found that insomnia prevalence 
Table 2. Prevalence of Sleep Disordersa
Sleep Disorder Older PWH (n = 219) Younger PWH (n = 102) Older HIV, Controls (n = 118)
Insomnia (ISI ≥15) 46 (21.0%) 23 (22.6%) 6 (5.1%)
 Medical history 10/46 (21.7%) 7/23 (30.4%) 1/6 (16.7%)
 Treatment history 9/46 (19.6%) 6/23 (26.1%) 1/6 (16.7%)
Restless Legs Syndrome (3 of 3 cardinal symptoms on IRLSSG questionnaire) 34 (15.5%) 8 (7.8%) 17 (14.4%)
 Medical history 1/34 (2.9%) 0/8 (0.0%) 2/17 (11.8%)
 Treatment history 0/34 (0.0%) 0/8 (0.0%) 2/17 (11.8%)
Sleep Apnea (ODI ≥5/hour) 16 (7.3%) 4 (3.9%) 9 (7.6%)
 Medical history 0/16 (0.0%) 0/4 (0.0%) 1/9 (11.1%)
 Treatment history 0/16 (0.0%) 0/4 (0.0%) 0/9 (0.0%)
Number of Sleep Disordersb    
 0 138 (63.0%) 69 (67.6%) 91 (77.1%)
 1 66 (30.1%) 31 (30.4%) 22 (18.6%)
 2+ 15 (6.9%) 2 (2.0%) 5 (4.2%)
Abbreviations: HIV, human immunodeficiency virus; IRLSSG, International Restless Legs Syndrome Study Group; ISI, Insomnia Severity Index; ODI, oxygen desaturation index; PWH, per-
sons with HIV.
aProportions of study participants meeting criteria for insomnia (by Insomnia Severity Index [ISI] questionnaire ≥15), restless legs syndrome (by reporting 3 of 3 cardinal symptoms on 
International Restless Legs Syndrome Study Group [IRLSSG] questionnaire), and sleep apnea (by overnight oximetry testing ODI ≥5/hour), along with distribution of those meeting criteria 
for zero, 1, or at least 2 sleep disorders. Also shown are participant-reported medical history of previous diagnoses and self-reported current or previous treatment, among those meeting 
criteria for the sleep disorder.
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by ISI ≥15 was 22% and did not vary by age [27]. Another 
recent study administered the Jenkins Sleep Problems Scale 
[28], which utilizes 4 questions directed at insomnia. In this 
study of 244 PWH and 244 HIV-negative controls recruited in 
2014–2015, the prevalence of insomnia was 19% in PWH and 
9% in the HIV-negative controls (P = .003) [29], which aligns 
very closely with our ISI-based prevalence estimates of 21% 
and 5%, respectively. That study also divided PWH into older 
and younger groups (mean ages of 47 and 63 years, which also 
aligns closely to our groupings of 46 and 60 years) and found 
no difference by age, which is also similar to our findings. As 
such, these emerging data indicate that PWH are at substan-
tially increased risk for insomnia compared with HIV-negative 
controls and that the presence of insomnia in PWH is not re-
lated to aging.
More importantly, insomnia in PWH was associated with 
decrements in health-related QoL measures. The association 
between insomnia and worse PROMIS sleep measures is per-
haps unsurprising, but we also observed strong associations be-
tween insomnia and worse SF-36 scores. Similar associations 
have been described in population-based samples [30] and re-
cently in a cohort of 103 PWH, where a clinical sleep interview 
found a very high insomnia prevalence of 67%—much higher 
than the studies using ISI questionnaires—and associations be-
tween insomnia and worse health-related QoL [31]. The mag-
nitude of the differences we observed in our cohort (7.9 points 
worse Physical and 12.9 points worse Mental Component 
scores) exceed the 3- to 5-point differences suggested as 
clinically important [32]. Our cross-sectional study design pre-
vented determination of the impact of insomnia treatment on 
health-related QoL in PWH, but our data suggest that such in-
tervention studies are needed.
The main treatment for insomnia, cognitive behavioral 
therapy for insomnia (CBT-I), is highly effective [33], but there 
are scant data regarding CBT-I in PWH [34], a population that 
may require tailored CBT-I due to biologic factors (eg, per-
sistent neuroinflammation despite effective viral suppression), 
social factors (eg, high burden of stigma and mental health dis-
orders), and polypharmacy. Insomnia in PWH may also be due 
to side effects of HIV antiretroviral treatment (ART), particu-
larly with efavirenz [35] and the integrase strand transfer inhib-
itor class of ART [36].
Other than ART drugs, PWH may also have additional bi-
ologic reasons for insomnia. Despite effective ART, PWH can 
demonstrate persistent central nervous system inflammation 
[37] and systemic inflammation [38]. Such inflammation might 
disrupt normal sleep homeostasis. Persons with HIV may also 
have additional psychosocial risk factors for insomnia such 
as mood disturbance, substance use, and stigma. We recently 
showed that higher self-reported pain severity related to higher 
ISI scores [39]. An analysis of risk factors for insomnia in PWH 
was beyond the scope of this particular analysis, but such fu-
ture analyses will be important to determine whether certain 
subgroups of PWH should be targeted for insomnia screening 
and treatment. From a clinical perspective, we emphasize that 
sedative or hypnotic drugs are not first-line treatments for 
Insomnia, Unadjusted
0 1 2 3 4 5
Odds Ratio (95% confidence interval)
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Figure 1. Association between human immunodeficiency virus status and odds of meeting criteria for sleep disorders: insomnia (by Insomnia Severity Index questionnaire), 
restless legs syndrome ([RLS] by International Restless Legs Syndrome Study Group questionnaire), and sleep apnea ([SA] by overnight oximetry testing). Unadjusted and 
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insomnia. For PWH with insomnia, we believe that CBT-I 
should still be considered the first-line treatment, pending the 
results of ongoing research to determine how to most effec-
tively deliver CBT-I to this unique population with potentially 
many opportunities for behavioral and lifestyle modifications 
to improve insomnia.
We are aware of only 2 published studies regarding RLS in 
PWH. In a single-center sample of 316 PWH enrolled in 2005–
2007 in San Francisco, California (mean age 45 years and 48% 
with detectable HIV-ribonucleic acid), 8.2% met questionnaire 
crietria for RLS at baseline [40], which is nearly identical to the 
7.8% we identified in our younger HIV sample with similar 
median age of 46  years. The study also included longitudinal 
follow-up of up to 2  years, during which an additional 3.2% 
met RLS criteria. Our study was only cross-sectional, but the 
higher prevalence of 15.5% in our older PWH group (median 
age 60 years) and the longitudinal San Francisco data suggest 
that RLS prevalence increases with aging in PWH, consistent 
with general population data.
The other study of RLS in PWH was a single-center, 
cross-sectional survey of 129 PWH (57% response rate, be-
cause 99 did not return the survey) and 100 healthy matched 
controls (response rate in controls not reported) in Munster, 
Germany. Thirty-three percent of the PWH (mean age 
44  years, 82% on ART) met questionnaire criteria for RLS, 
compared with 7% of the age-matched HIV-negative controls 
[41]. Their data are contrary to our findings of no difference 
in RLS prevalence by HIV status, and their RLS prevalence 
in PWH far exceeds the 8% prevalence seen in similarly aged 
participants in both our study and the San Francisco study. 
Reasons for the discrepancy are not clear, but survey sam-
pling methods can introduce survey response bias, in which 
symptomatic PWH may have been more likely to respond 
to the survey than those without symptoms. Nevertheless, 
Table 3. Patient- Reported Outcomes and Insomniaa
Outcome
PWH (n = 321) HIV-negative (n = 118)
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Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus, PROMIS, Patient-Reported Outcomes Measurement Information System; PWH, persons with HIV; RLS, restless 
legs syndrome; SA, sleep apnea; SF-36, 36-item Short Form.
aAssociation of insomnia with patient-reported outcomes, stratified by HIV status and with P value tests for interactions by HIV status. Group values are shown as median (interquartile range) 
and differences as adjusted difference (95% CI). For SF-36 Physical Component and Mental Component Scores, lower scores indicate worse health-related quality of life. For patient-reported 
outcomes Measurement Information System (PROMIS) questionnaires for sleep disturbance and sleep-related impairment, higher scores indicate worse health-related quality of life.
bAdjusted for age, sex, and ethnicity.
Table 4. Patient-Reported Outcomes and Restless Legs Syndromea
Outcome
PWH (n = 321) HIV-negative (n = 118)
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Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus, PROMIS, Patient-Reported Outcomes Measurement Information System; PWH, persons with HIV; RLS, restless 
legs syndrome; SF-36, 36-item Short Form.
aAssociation of restless legs syndrome with patient-reported outcomes, stratified by HIV status and with P value tests for interactions by HIV status. Group values are shown as median 
(interquartile range) and differences as adjusted difference (95% CI). For SF-36 Physical Component and Mental Component Scores, lower scores indicate worse health-related quality of 
life. For patient-reported outcomes Measurement Information System (PROMIS) questionnaires for sleep disturbance and sleep-related impairment, higher scores indicate worse health-
related quality of life.
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we found that RLS was not related to health-related QoL in 
PWH, compared with the very strong associations between 
insomnia and these patient-centered outcomes. Given high 
demands on HIV clinician time and limited research re-
sources, our data suggest that clinical and research efforts 
might benefit from prioritizing time and effort towards in-
somnia over RLS.
Sleep apnea has received recent attention in PWH, partially 
due to a rising prevalence of older age and obesity—2 major risk 
factors for SA—and data suggesting that SA might contribute to 
common HIV comorbidities such as cardiovascular disease [4]. 
Preliminary studies suggest that PWH have a high prevalence 
of SA symptoms and risk factors [13, 42], but few studies have 
performed objective testing for SA in PWH. The largest pub-
lished study with such data that we are aware of came from the 
Baltimore site of the Multicenter AIDS Cohort Study (MACS). 
In a convenience sample (100% male, n = 99 PLWH and n = 60 
HIV-negative controls) who underwent formal in-laboratory 
polysomnogram (PSG), SA prevalence in PWH was 72% [12]. 
Although this was a strikingly high prevalence of SA, uninfected 
controls had an even higher prevalence of SA (87%), again sug-
gesting the possibility of sampling bias, where men with sleep 
symptoms may have been more likely to participate in the study 
than those without symptoms.
Only 6% of our PWH met criteria for SA. We note that our 
SA assessment was limited to overnight oximetry rather than 
the PSG assessments in MACS. Overnight oximetry may 
slightly underestimate SA severity [18, 19] and might also fail to 
identify some forms of SA such as upper airway resistance syn-
drome (UARS) in which mild forms of apneas and hypopneas 
can lead to cortical arousals and disrupted sleep without classic 
oxygen desaturation events. This would seem unlikely to explain 
the remarkably large difference in SA prevalence between the 
POPPY and MACS studies, but UARS is associated with in-
somnia [43], so we cannot exclude the potential for a higher 
prevalence of UARS in our cohort. Major risk factors for SA (eg, 
age, body mass index, neck circumference) were very similar 
in both cohorts, so these would not appear to explain the dif-
ference in SA prevalence. More importantly, both our POPPY 
study and the MACS study found no difference in SA preva-
lence by HIV status, suggesting that HIV does not uniquely 
lead to SA. Further longitudinal research remains important to 
determine whether the impact of SA in PWH differs from the 
impact in HIV-negative persons.
Strengths of our study include its multicenter enrollment of 
study participants from an ongoing cohort study, not selected 
on the basis of sleep symptoms, and its simultaneous assess-
ment of multiple sleep outcomes. Some important limitations 
are also worth noting. Our criteria for insomnia, RLS, and SA 
are not diagnostic. The gold standard evaluation for insomnia is 
a standardized diagnostic clinical interview. Diagnosis for RLS 
requires further history and exclusion of other conditions (eg, 
neuropathy, pain syndromes). Sleep apnea was only assessed 
by overnight oximetry rather than more standard diagnostic 
sleep studies, and overnight oximetry has not been validated for 
SA diagnosis in PWH. Our cross-sectional assessment did not 
allow us to assess the long-term impact of insomnia, RLS, and 
SA on clinical outcomes.
CONCLUSIONS
More than 20% of PWH meet questionnaire criteria for in-
somnia, which is associated with significantly worse physical, 
mental, and sleep-related QoL. Persons with HIV are approxi-
mately 5 times more likely than matched HIV-negative controls 
Table 5. Patient-Reported Outcomes and Sleep Apneaa
Outcome
PWH (n = 321) HIV-negative (n = 118)
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Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus, PROMIS, Patient-Reported Outcomes Measurement Information System; PWH, persons with HIV; SA, sleep 
apnea; SF-36, 36-item Short Form.
aAssociation of sleep apnea with patient-reported outcomes, stratified by HIV status and with P value tests for interactions by HIV status. Group values are shown as median (interquartile 
range) and differences as adjusted difference (95% CI). For SF-36 Physical Component and Mental Component Scores, lower scores indicate worse health-related quality of life. For patient-
reported outcomes Measurement Information System (PROMIS) questionnaires for sleep disturbance and sleep-related impairment, higher scores indicate worse health-related quality of life.






/ofid/article/8/1/ofaa561/5989004 by guest on 05 January 2021
8 • ofid • Kunisaki et al
to meet insomnia criteria, yet few report prior diagnosis and 
treatment for insomnia. Restless legs syndrome and SA were 
less common than insomnia, not associated with HIV status, 
and not as strongly associated with health-related QoL. Further 
research should focus on insomnia pathogenesis in PWH and 
development of effective screening and intervention strategies 
for PWH.
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online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility 
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